Karyopharm Therapeutics Priced, Nasdaq: KPTI
Early-stage biotech developing treatments for cancer by targeting nuclear transport.
Industry: Health Care
First Day Return: +0.3%
KPTI
Early-stage biotech developing treatments for cancer by targeting nuclear transport.
| IPO Data | |
|---|---|
| IPO Date | 11/05/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $109 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Natick, MA, United States |
| Founded | 2008 |
| Employees at IPO | 23 |
| Website www.karyopharm.com | |
IPO News for Karyopharm Therapeutics
Karyopharm Therapeutics (KPTI) Performance
